Big Pharma has been in the news a lot lately – from the Supreme Court decision on “Obamacare” to the troubling fine that GlaxoSmithKline (GSK) faces – but for Bristol-Myers (BMY) Squibb, the news has been mostly positive (and with GlaxoSmithKline pleading guilty to introducing two misbranded drugs to interstate commerce, a big competitor for Bristol-Myers Squibb has had its image tarnished).
The company has purchased the diabetes drug maker Amylin Pharmaceuticals (AMLN) $5.3 billion. This is a huge step for Bristol-Myers Squibb and its forward progress in the world of diabetes treatment. Prior to this acquisition, Amylin was trading around $30.70 per share and had a market cap for 5.00 billion. In addition to being financially successful for Bristol-Myers Squibb, this move will be incredible for the financial status of Amylin. The price of the acquisition is expected to increase to around $7 billion after Amylin’s debt to Eli Lilly (LLY) is factored in. Eli Lilly & Company is currently strong at $40.85 per share (towards the high end of its 52-week range) and has a dividend yield of $0.49/$4.57. Basically, Bristol-Myers will pay off Amylin’s debt to the pharmaceutical giant, making Bristol-Myers an even greater competitor to Eli Lilly & Company.
Eli Lilly, along with its partner Incyte (INCY) has had massive success in the trials of its up and coming rheumatoid arthritis. The drug, Baricitinib, has achieved all of its primary goals thus far. This news is a game changer for Eli Lilly.To continue reading, click here.
Bristol-Myers Squibb: Don’t Miss This Attractive Entry Point
Big Pharma has been in the news a lot lately – from the Supreme Court decision on “Obamacare” to the troubling fine that GlaxoSmithKline (GSK) faces – but for Bristol-Myers (BMY) Squibb, the news has been mostly positive (and with GlaxoSmithKline pleading guilty to introducing two misbranded drugs to interstate commerce, a big competitor for Bristol-Myers Squibb has had its image tarnished).
The company has purchased the diabetes drug maker Amylin Pharmaceuticals (AMLN) $5.3 billion. This is a huge step for Bristol-Myers Squibb and its forward progress in the world of diabetes treatment. Prior to this acquisition, Amylin was trading around $30.70 per share and had a market cap for 5.00 billion. In addition to being financially successful for Bristol-Myers Squibb, this move will be incredible for the financial status of Amylin. The price of the acquisition is expected to increase to around $7 billion after Amylin’s debt to Eli Lilly (LLY) is factored in. Eli Lilly & Company is currently strong at $40.85 per share (towards the high end of its 52-week range) and has a dividend yield of $0.49/$4.57. Basically, Bristol-Myers will pay off Amylin’s debt to the pharmaceutical giant, making Bristol-Myers an even greater competitor to Eli Lilly & Company.
Eli Lilly, along with its partner Incyte (INCY) has had massive success in the trials of its up and coming rheumatoid arthritis. The drug, Baricitinib, has achieved all of its primary goals thus far. This news is a game changer for Eli Lilly.To continue reading, click here.
Posted in Tech News